Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 13/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | NRAS | P01111 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.39 |
| ▸ | BLK | P51451 | 2/20 | 0.39 |
| ▸ | CCNH | P51946 | 2/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832037 | 0.83 | CYP1A2 (0.43) | PRMT5WDR77FLT3POLB | |
| SCHEMBL4036874 | 0.80 | PRMT5 (0.44) | PRMT5WDR77FLT3RET | |
| SCHEMBL2263881 | 0.77 | FLT3 (0.47) | PRMT5WDR77FLT3IRAK4 | |
| Hydrochloric Acid SCHEMBL4032782 | 0.76 | FLT3 (0.46) | PRMT5WDR77FLT3IRAK4 | |
| SCHEMBL2261411 | 0.71 | PRMT5 (0.40) | PRMT5WDR77 | |
| Formaldehyde SCHEMBL28021001 | 0.68 | CHEK1 (0.48) | PRMT5WDR77FLT3IRAK4NRAS | |
| SCHEMBL2265404 | 0.68 | MKNK1 (0.50) | PRMT5WDR77 | |
| SCHEMBL28041698 | 0.66 | POLB (0.54) | PRMT5WDR77EIF2AK4FLT3IRAK4 | |
| SCHEMBL4034194 | 0.66 | PRMT5 (0.43) | PRMT5WDR77 | |
| SCHEMBL2261834 | 0.66 | CDK8 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | PRMT5 809/4885WDR77 1243/4885EIF2AK4 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.